Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHFR | P00374 | 6/20 | 0.61 |
| ▸ | SLC2A1 | P11166 | 8/20 | 0.61 |
| ▸ | F2R | P25116 | 4/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26324789 | 1.00 | DHFR (0.61) | DHFRSLC2A1F2R | |
| SCHEMBL9568637 | 0.82 | DHFR (0.73) | DHFRSLC2A1F2R | |
| SCHEMBL9568513 | 0.78 | SLC2A1 (0.81) | DHFRSLC2A1F2R | |
| SCHEMBL9568542 | 0.76 | DHFR (1.00) | DHFRSLC2A1F2R | |
| SCHEMBL24164676 | 0.76 | DHFR (0.58) | DHFRSLC2A1F2R | |
| SCHEMBL9568734 | 0.76 | SLC2A1 (1.00) | DHFRSLC2A1F2R | |
| SCHEMBL9568566 | 0.76 | SLC2A1 (1.00) | DHFRSLC2A1F2R | |
| Water SCHEMBL9568544 | 0.75 | DHFR (0.97) | DHFRSLC2A1F2R | |
| SCHEMBL9568740 | 0.74 | SLC2A1 (0.97) | DHFRSLC2A1F2R | |
| SCHEMBL11614486 | 0.73 | F2R (0.78) | DHFRSLC2A1F2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230295164-A1 | COMPOUNDS HAVING ANTIBACTERIAL ACTIVITY | PEKING UNIVERSITY SHENZHEN GRADUATE SCHOOL (CN) | 2023-09-21 | — | — | US | disclosed |
| US-20230295164-A1 | COMPOUNDS HAVING ANTIBACTERIAL ACTIVITY | PEKING UNIVERSITY SHENZHEN GRADUATE SCHOOL (CN) | 2023-09-21 | — | — | US | disclosed |
| US-20230242540-A1 | COMPOUNDS HAVING ANTICANCER ACTIVITY | THE TRUSTEES OF PRINCETON UNIVERSITY | 2023-08-03 | — | — | US | disclosed |
| US-20230242540-A1 | COMPOUNDS HAVING ANTICANCER ACTIVITY | THE TRUSTEES OF PRINCETON UNIVERSITY | 2023-08-03 | — | — | US | disclosed |
| WO-2022006447-A1 | COMPOUNDS HAVING ANTICANCER ACTIVITY | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 2022-01-06 | — | — | WO | disclosed |
| WO-2022006432-A1 | COMPOUNDS HAVING ANTIBACTERIAL ACTIVITY | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 2022-01-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230295164-A1 | COMPOUNDS HAVING ANTIBACTERIAL ACTIVITY | CFTR, MRPL21, MPO | DHFR 538/4885SLC2A1 3013/4885F2R 3396/4885 |
| US-20230242540-A1 | COMPOUNDS HAVING ANTICANCER ACTIVITY | TP53, KRAS, MKI67 | DHFR 183/4885SLC2A1 4036/4885F2R 4267/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.